Article By:
Zacks Investment Research
Sunday, April 3, 2016 7:19 AM EDT
The entry of the first FDA-approved biosimilar, Zarxio, a biosimilar version of Amgen’s blockbuster drug, Neupogent, last year has left biotech companies vying to enter this high revenue generating space. Biosimilars are the next big thing.
Four Best Biotech Stocks of the First Quarter of 2016
Would like to see more on $KIN, thanks.